Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
Establishment Labs Holdings, Inc. has a significant shareholder group led by JW Asset Management, LLC and related entities, which collectively report beneficial ownership of 2,692,856 common shares. These shares represent 9.15% of the outstanding common stock, based on 29,430,390 shares outstanding as of May 7, 2026, as referenced from the issuer’s quarterly report.
JW Asset Management, LLC, JW GP, LLC, and Jason G. Wild each report shared voting and dispositive power over 2,692,856 shares, while JW Partners reports 2,006,252 shares (6.82%) and JW Opportunities Fund, LLC reports 686,604 shares (2.33%). All reporting persons list 0 shares with sole voting or dispositive power, indicating that voting and disposition authority is shared for these positions.
BlackRock, Inc. reported beneficial ownership of common stock of Establishment Labs Inc. BlackRock and certain of its business units collectively beneficially own 1,576,071 shares of common stock, representing 5.4% of the class as of June 30, 2026.
BlackRock has sole voting power over 1,535,124 shares and sole dispositive power over 1,576,071 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than five percent of the outstanding common shares.
Chacon Quiros Juan Jose reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros received a grant of 11,315 Common Shares as a stock unit award under the company’s 2018 Equity Incentive Plan, at a stated price of $0.0000 per share. One-fourth of the shares subject to the award vest on April 24, 2027 and on each one-year anniversary thereafter, contingent on continued service. Following this grant, he holds 56,508 Common Shares directly and 927,504 Common Shares indirectly through Sariel Group Ltd, where he has voting and dispositive power but disclaims beneficial ownership beyond his pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received a grant of stock options covering 19,561 common shares at an exercise price of $66.28 per share, expiring on April 24, 2036. One-fourth of these options vest on April 24, 2027 and on each one-year anniversary thereafter, subject to continued service. Following the transactions, he held 1,079,960 common shares directly and 19,090 common shares indirectly through his spouse, plus the newly granted options.
Harris Taylor C. reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Harris Taylor C. received two equity awards in the form of stock units representing common shares. One grant covers 1,773 common shares, and another covers 1,949 common shares, both awarded at no cash cost as director compensation under the company’s 2018 Equity Incentive Plan.
The 1,773-share award vests in three equal annual installments on each yearly anniversary of the grant date, subject to continued service. The 1,949-share award vests in full on the earlier of June 24, 2027 or the day before the next annual stockholder meeting, also contingent on ongoing service.
Gillin Leslie reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Leslie Gillin received 196 common shares as a stock grant on June 30, 2026. The shares were elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy and issued under the 2018 Equity Incentive Plan, based on a closing price of $85.81 per share. Following this compensation-related award, Gillin directly holds 18,594 common shares.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Ann Custin received an equity grant of common shares as part of her board compensation. She was awarded 239 common shares, elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the 2018 Equity Incentive Plan at a reference price of $85.81 per share, based on the closing price on the last trading day of the quarter. Following this grant, Custin directly holds 24,325 common shares of the company.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Nicholas Sheridan Lewin received 291 common shares as a stock grant. These shares were elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy and were issued under the 2018 Equity Incentive Plan, using a reference price of $85.81 per share.
After this grant, Lewin directly holds 1,079,960 common shares. An additional 19,090 common shares are reported as indirectly owned and are held by his spouse.
SCHUTTER EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Edward J. Schutter received a grant of 216 common shares on June 30, 2026, valued using a price of $85.81 per share. These shares were elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy, bringing his direct holdings to 177,952 shares.
Slotkin Bryan reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Bryan Slotkin reported receiving 189 common shares as compensation. These shares were granted in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy, based on a closing share price of $85.81. Following this award, Slotkin directly holds 32,799 common shares.